新秀丽(01910):美国双重上市估值重估潜力遭忽略,评级"买入" 瑞银华宝 瑞银近期收到不少投资者查询，询问新秀丽自2月中旬公布美国双重上市进展以来，其股价疲弱(下跌6%) 的根本原因。瑞银从投资者反馈中得悉，股价疲弱或归因于集团对高达15%的发行价折让，以及相关股份稀释 的担忧，认为忧虑掩盖了集团在美国上市后，可能获得与全球同业看齐的估值重估潜力。 瑞银近期又从全球航空公司、线上旅行社、酒店及奢侈品公司公布的业绩中，看到相对正面的启示，上述 公司业绩或对集团收入趋势具有指标性意义。而在过去七个季度中，新秀丽的收入趋势与LVMH高度相关。 瑞银发布研报称，预计近期美国最高法院对美国关税合法性的裁决及之后的关税调整，应能在未来五个月 内，有效降低新秀丽(18.7,-0.54,-2.81%)(01910)面对的关税率约低至中单位数百分比;料其美国批发客户或 利用该窗口期，在旅游需求强劲的背景下补充库存，从而推动集团在美国市场的收入复苏;予该股目标价24.8 港元，评级"买入"。 ...

Core Insights - Pfizer's total revenue for 2025 was $62.6 billion, a 2% year-over-year decline, but core business revenue grew by 6% when excluding COVID-19 products, indicating robust growth in non-COVID segments [1] - Adjusted EPS for 2025 was $3.22, a 4% increase, driven by cost-cutting measures and improved operational efficiency [1] - The management reaffirmed its 2026 guidance, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS projected at $2.80 to $3.00 [1] Financial Performance - In Q4 2025, Pfizer's revenue reached $17.6 billion, with a 9% year-over-year increase when excluding COVID-19 products, highlighting accelerated business transformation [1] - Non-COVID products like the anticoagulant Eliquis generated $8 billion in revenue (up 8%), and the pneumonia vaccine Prevnar contributed $6.5 billion, providing stable growth to offset declines in COVID-related sales [3] Market Analysis - According to a report by CMB International, Pfizer's Q4 performance exceeded expectations, with promising data from the weight-loss pipeline PF'3944 showing a 12.3% weight reduction in the mid-dose group, indicating competitive potential against Eli Lilly's tirzepatide [2] - Analyst ratings for Pfizer range from $26 to $30, with Scotiabank maintaining a "Buy" rating and a target price of $30, emphasizing improvements in cash flow and pipeline catalysts [2] Stock Performance - Over the past week (February 5 to 11, 2026), Pfizer's stock price fluctuated by 3.55%, with a range of $26.46 to $27.94, closing at $27.73 on February 11, reflecting a daily increase of 0.43% and a trading volume of $1.157 billion [4] - Year-to-date, Pfizer's stock has risen by 13.23%, outperforming the pharmaceutical sector, which saw a slight decline of 0.02% during the same period [4]

Investment Rating - The report maintains a neutral stance on Mitsui & Co., indicating limited attractiveness in current valuations despite expectations for profit growth and a new mid-term plan to be announced by year-end [4][5]. Core Insights - Mitsui & Co. reported a third-quarter net profit of 188 billion JPY, a 32% year-on-year decline, which fell short of the market consensus of 194.5 billion JPY. The company maintained its full-year guidance of 820 billion JPY net profit, although adjustments were made to its components due to various factors impacting profitability [4][5]. - The report highlights that the company's core operating cash flow reached 950 billion JPY, achieving a completion rate of 83%, prompting an upward revision of the full-year guidance by 50 billion JPY to 950 billion JPY [5]. - Key catalysts for potential growth include fluctuations in commodity prices, cash surges driven by asset cycles, and improvements in returns from non-resource investments [6]. Company Overview - Mitsui & Co. is the second-largest general trading company in Japan by market capitalization and total sales, with 60-70% of its net profit derived from natural resources, including oil, gas, iron ore, coal, and copper. The remaining profit comes from non-resource sectors such as machinery and chemicals [8]. - The company has shifted its focus from setting profit targets to a return on equity (ROE) orientation, emphasizing profitability over absolute profit. Its strengths lie in brand reputation, accumulated experience, talent reserves, and capital acquisition capabilities [8]. Revenue Breakdown - Revenue by product category: Lifestyle Industry (24.1%), Energy (22.1%), Chemicals (20.9%), Metal Resources (15.3%) [9]. - Revenue by geographical region: Asia (82.7%), Americas (8.1%), Europe (7.0%), Middle East and Africa (2.2%) [9]. Stock Information - Stock price as of February 3, 2026: 5,147 JPY, with a 12-month high/low of 5,156 JPY/2,470 JPY. Market capitalization stands at 89.47 billion USD [9][10]. - The market consensus target price is set at 4,768.50 JPY [10].

Core Viewpoint - Morgan Stanley believes that the ongoing recovery of tenant sales in mainland China will drive a revaluation of Hang Lung Properties (00101), raising the target price from HKD 11.5 to HKD 12, making it one of the bank's top picks [1] Group 1: Financial Performance - The performance for the fiscal year 2025 confirms a recovery in tenant sales for Hang Lung Properties, with a year-on-year growth of 18% in Q4 2025, reaching a historical high, compared to a 10% year-on-year growth in Q3 2025 [1] - Management anticipates a mid-single-digit percentage growth in tenant sales for the fiscal year 2026, with positive momentum continuing until January 2026 [1] Group 2: Valuation and Market Position - Hang Lung Properties is currently trading at a 66% discount to net asset value, with a price-to-book ratio of 0.3 and a dividend yield of 5.5%, indicating that the company is still undervalued [1] - Despite low single-digit growth of international luxury brands in China, investors may overlook the strong growth of non-luxury brands, which account for half of tenant sales [1] Group 3: Rental Income Strategy - There are concerns among some investors regarding the lag in rental income growth compared to tenant sales growth; however, Morgan Stanley believes that they underestimate Hang Lung Properties' efforts to convert more variable rent into fixed rent, which helps stabilize rental income during downturns [1]

Core Viewpoint - Morgan Stanley believes that the ongoing recovery of tenant sales in mainland China will lead to a revaluation of Hang Lung Properties (00101), raising the target price from HKD 11.5 to HKD 12, making it one of the bank's top picks [1] Group 1: Financial Performance - The performance for the fiscal year 2025 confirms a recovery in tenant sales for Hang Lung Properties, with a year-on-year growth of 18% in Q4 2025, reaching a historical high, surpassing the 10% year-on-year growth in Q3 2025 [1] - Management anticipates a mid-single-digit percentage growth in tenant sales for the fiscal year 2026, with positive momentum continuing until January 2026 [1] Group 2: Valuation Metrics - Hang Lung Properties is currently trading at a 66% discount to net asset value, with a price-to-book ratio of 0.3 and a dividend yield of 5.5%, indicating potential upward risk starting from the fiscal year 2027 [1] - The bank considers Hang Lung Properties to be undervalued based on these metrics [1] Group 3: Market Position and Growth Drivers - Hang Lung Properties operates as a "luxury retail agent" in China, where international luxury brands are experiencing low single-digit growth, which may not seem attractive [1] - However, investors may overlook the strong growth of non-luxury brands, which account for half of tenant sales [1] - There is a perception that rental income growth is lagging behind tenant sales growth, but Morgan Stanley believes this underestimates Hang Lung Properties' efforts to convert more variable rents into fixed rents, which helps stabilize rental income during downturns [1]

Core Viewpoint - Morgan Stanley's report indicates that the performance for the fiscal year 2025 confirms the recovery of tenant sales for Hang Lung Properties, with a year-on-year growth of 18% in Q4 2025, marking a historical high, surpassing the 10% year-on-year growth in Q3 2025 [1] Group 1 - The management anticipates a mid-single-digit percentage growth in tenant sales for the fiscal year 2026, with positive momentum maintained as of January 2026 [1] - Hang Lung Properties is currently undervalued based on a 66% discount to net asset value, a price-to-book ratio of 0.3, and a dividend yield of 5.5%, with upward risks starting from the fiscal year 2027 [1] - The sustained recovery of tenant sales in mainland China is expected to drive a revaluation of Hang Lung Properties, leading to an increase in the target price from HKD 11.5 to HKD 12, maintaining its status as a preferred choice [1]

Core Viewpoint - Morgan Stanley reaffirms "Overweight" rating for New Oriental-S (09901) and raises target price from HKD 53 to HKD 55 [1] Financial Performance - New Oriental's Q2 FY2026 results exceeded expectations and guidance was raised for the first time in two years [1] - Management's optimistic outlook led to a 7% increase in operating profit forecasts for FY2026 to FY2027 [1] Growth Potential - The company is back on a "high-quality compound growth" track, with expectations for continued performance exceeding forecasts and upward guidance adjustments [1] - The market has not fully recognized the company's profit potential and compounding effects [1] Earnings and Valuation - The annual compound growth rate for earnings per share exceeds 15%, supporting a revaluation of the company's stock [1] - Investors can expect over 5% annual capital returns, backed by USD 5.6 billion in net cash [1]

Summary of Key Points from Conference Call Records Industry Overview - The global metal market is characterized by weak interest rate cuts, weak recovery, and weak recession, leading to prolonged cycle transmission times. Gold and industrial metals are in the early stages of a rebound, with potential for further growth as interest rate cuts lead to industrial recovery [1][3]. - The global manufacturing PMI data shows slight stabilization, with China and the US still at the bottom. Aluminum has become a significant representative of China's manufacturing sector, benefiting from low-cost advantages and a complete industrial chain [1][5]. Key Insights and Arguments - **Aluminum Market Dynamics**: - China consumes approximately 450 million tons of electrolytic aluminum, accounting for 6%-7% of national electricity usage. The country has successfully captured upstream ore profits through capacity constraints and earns profits from aluminum exports [1][6]. - The US may shift focus from copper to aluminum inventory replenishment due to significant demand in manufacturing and AI applications [1][6]. - **Profit Recovery and Dividend Increases**: - Industries such as coal, oil, and aluminum have entered a phase of profit and debt recovery, leading to substantial dividend increases. The average dividend payout ratio in the power sector has risen to 50%, indicating a transition to a dividend era for China's manufacturing sector [1][8]. - **Chemical Industry Transformation**: - The chemical industry is expected to undergo significant changes on the supply side, leading to a revaluation of overall industry valuations. China remains the largest producer and supplier of chemical products globally, with a competitive edge as long as domestic capacity is constrained [1][12][13]. Potential Investment Opportunities - **Aluminum Sector**: - Recommended companies include integrated firms like Tianshan, Hongchuang, Nanshan, and others. Non-integrated companies with higher elasticity such as Shuanghuo, Yun Aluminum, and Huadong are also worth considering [1][11]. - **Chemical Sector**: - The chemical sector currently shows no significant bubbles, with valuations below 10 times earnings, indicating good investment potential. Key companies to watch include Wanhua Chemical, Longbai Group, and others [1][16]. Future Trends and Projections - **Aluminum Price Outlook**: - Future aluminum prices may recover to levels above 30,000 yuan, with historical peaks during energy crises providing a benchmark. Seasonal inventory replenishment may also drive price increases [1][7]. - **Aviation Sector Forecast**: - The aviation sector is expected to experience significant price increases by 2026 due to supply constraints and changing demand structures. The pandemic has altered the supply dynamics, with a projected decline in actual supply from 2026 to 2028 [1][19][21]. - **Demand Shifts in Aviation**: - Post-pandemic, domestic tourism demand is expected to grow at 3%-4% annually, while foreign entry demand is projected to increase significantly. This shift may lead to a sustained price increase cycle in the aviation industry [1][22][23]. Additional Important Insights - The chemical industry is cyclical, with demand linked to GDP growth. However, supply-side changes may lead to significant revaluation opportunities [1][12][15]. - The oil and petrochemical sectors are at the beginning of a global economic cycle, with supply constraints driving up prices for by-products [1][4][17]. - The overall investment landscape is shifting towards resource-based products, with potential for significant returns as manufacturing transitions to resource-oriented models [1][9][10].

Core Viewpoint - Morgan Stanley's report indicates that Weichai Power's stock price has outperformed the market since October last year, as investors begin to recognize the company's transition from a cyclical traditional engine business to a growth platform centered on AIDC and new energy solutions [1] Group 1: Company Performance - Weichai Power's stock price has shown significant growth, outperforming the market since October of the previous year [1] - The market is currently focused on the strong momentum of AIDC backup engines, but has not yet fully reflected the scale of opportunities in the aftermarket [1] Group 2: Valuation and Target Price - Morgan Stanley believes that the valuation re-rating of Weichai Power is still in its early stages [1] - The target price for Weichai Power's A-shares has been raised from 31 yuan to 36 yuan, and the target price for H-shares has been increased from 31 Hong Kong dollars to 36 Hong Kong dollars [1] - The rating for Weichai Power remains "overweight," and it continues to be one of the preferred stocks in the industry [1]

Investment Rating - The report indicates a positive investment outlook for WuXi AppTec, with a consensus target price of HKD 131.35, suggesting potential upside from the current price of HKD 110.8 [13]. Core Insights - WuXi AppTec reported a 9% year-over-year revenue growth for Q4 2025, with adjusted net profit increasing by 36%, exceeding market expectations by 2% and 3% respectively [5]. - The strong performance is attributed to the company's robust CRDMO integrated business model and significant growth in the WuXi TIDES business, alongside China's competitive position in the global small molecule supply chain [5]. - Looking ahead to 2026, earnings realization in the Chinese healthcare sector is expected to be more critical than valuation expansion [5]. Summary by Sections Financial Performance - WuXi AppTec's revenue for 2025 increased by 15.8% to CNY 45.5 billion, with core business sales rising by 21.4%, surpassing previous guidance by 3-4% and Bloomberg consensus by 2% [8]. - Adjusted net profit rose by 41.3% to CNY 15 billion, again exceeding market expectations by 3% [8]. - The company has shown a 41% year-over-year increase in order volume for the first nine months of 2025, significantly outpacing the global average growth rate of 14% [8]. Business Overview - WuXi AppTec operates as a global enterprise with services spanning small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular diagnostics and genomics [9]. - The company provides comprehensive services throughout the R&D cycle, supporting global innovation and transformative therapies [9]. Market Position - WuXi AppTec's order growth visibility is superior to its peers, with expectations for continued outperformance in 2026 [8]. - The potential for margin expansion exists through the divestiture of low-margin clinical CRO businesses and an acceleration in order growth in 2026 [8].